DENVER (PRWEB)
April 19, 2022

Pathware Inc., a MedTech company developing hardware and software to bring digital pathology from the central lab to the point-of-care, today announced it secured $7 million in an oversubscribed Series A financing. The funding will be used to continue expanding the team and to submit the integrated hardware and software system to the FDA for clearance.

The financing round coincides with MedTech veteran TJ Meyer joining Pathware as CEO. Mr. Meyer most recently led global marketing, strategy, clinical support, and business development at Veran Medical Technologies, a medical device company focused on the early diagnosis and staging of lung cancer. During Mr. Meyer’s tenure, Veran grew revenues from $2 million to $30 million and was acquired by Olympus in December of 2020.

“I am excited to join Pathware and am fortunate to work alongside such a talented team. Our mission of bringing digital pathology to the point-of-care will help pathologists and proceduralists diagnose cancer earlier and ultimately save patient lives,” said Mr. Meyer. “We could not be more excited to have strong investors, as well as many industry experts show their belief in our team, technology, and market by making personal investments. More importantly, it is a dream come true to see the value these sophisticated investors can add beyond their dollar in helping us achieve our mission.”

The Series A financing was co-led by UnityPoint Health Ventures and Level Eight Ventures with participation from existing investors. Also participating in the round are MVolution Partners, an investment firm focused on providing growth capital to innovative healthcare and technology companies, and Solas BioVentures, a venture capital firm that invests exclusively in the life science industry.

“While there has been tremendous progress applying artificial intelligence to digital pathology software, there has been no meaningful innovation in digital pathology hardware over the last two decades,” said Austin Duke, PhD, Venture Investing Director at UnityPoint Health Ventures. “We are excited for Pathware’s hardware and software innovations to enable new workflows and applications, as well as extend the reach of pathologists for the 90% of hospitals that are unable to staff pathologists on site. Just as important, we believe these advances will improve patient outcomes.”

“We are grateful for the opportunity to support Pathware’s development and commercialization activities through our capital and network of value-added investors,” said Mike Weinmann, Founding Partner at MVolution Partners. “The executive team’s highly-relevant experience and skillset, coupled with game-changing technology and a substantial total addressable market, make Pathware one of the most compelling investments we have made over our careers.”

The Series A financing includes participation from noteworthy investors, including Sidney Taurel (former CEO & Chairman at Eli Lilly), Steve Laczynski (former CEO of Philips Healthcare Americas and former VP at Quest Diagnostics), Monica Richter (former Chief Data Officer at Dun & Bradstreet and former SVP of Data Strategy at S&P Global), David Johnson (founder of Caligan Partners), James Watt (President, Enterprise Distribution & Partnership Growth at Cigna), and Peter Faroni (private investor and former Founder & Managing Member of Madryn Asset Management).

About Pathware Inc.

Pathware is a privately held MedTech company based in Denver, CO and with offices in Seattle, WA. The company is focused on developing hardware and software to bring digital pathology from the central lab to the point-of-care. For more information, please visit: pathware.com.

About UnityPoint Health Ventures

Founded in 2019, UnityPoint Health Ventures makes direct investments in ideas and partners that provide an easier, more personal experience for patients and providers. As the venture capital arm of UnityPoint Health – one of the nation’s most integrated health systems – the firm invests in opportunities that improve patient outcomes and reduce the cost of health care. In addition to strategic investing, UnityPoint Health Ventures provides dedicated resources to accelerate portfolio company traction within UnityPoint Health and beyond. Through relationships with more than 450 physician clinics, 20 regional and 19 community network hospitals in metropolitan and rural communities and home care services throughout its 9 regions, UnityPoint Health provides care throughout Iowa, western Illinois, and southern Wisconsin. More at uphventures.org.

About Level Eight Ventures

Level Eight Ventures is a venture capital firm that invests in early-stage companies developing core products which positively impact the physical world or improve the human condition. Hands-on investors with diverse experience commercializing new technologies and entering new markets, Level Eight’s principals actively advise and support its portfolio companies in North America and Europe as they navigate obstacles to funding and growth. With offices in Ann Arbor and Philadelphia, Level Eight leverages extensive relationships with incubators, technology transfer offices, and centers of innovation in the booming Michigan to Ontario technology corridor, while its Cambridge, England office provides direct access to tech startups in Europe and the UK. For more information, please visit level8.vc.

About MVolution Partners

MVolution Partners (MVP) provides growth capital solutions from $1 million to $100 million to healthcare and technology companies. MVP targets equity and debt investments in North America and Europe and provides operational, strategic, and sustainability value add to achieve shared success with its portfolio companies. The founding partners of MVP have been responsible for $4 billion of principal investments and have advised on over $40 billion of capital markets and mergers and acquisitions activity. For more information, please visit mvolutionpartners.com.

About Solas BioVentures

Solas BioVentures is a venture capital firm that invests exclusively in the life science industry, focusing primarily on early and development stage biotech and medtech companies advancing impactful, disruptive technologies. Headquartered in Chattanooga, Tennessee, its coverage is global. For more information, please visit solasbio.com.

Share article on social media or email:

NEW YORK (PRWEB)
April 19, 2022

Mount Sinai Innovation Partners (MSIP), the commercialization arm of the Mount Sinai Health System in New York, New York, has launched i3 Prism, a technology commercialization fund focused on women and Black, Indigenous and people of color (BIPOC) health care innovators.

This unique opportunity empowers diverse innovators, including Mount Sinai’s faculty, staff, and students, to help advance technologies and develop commercialization plans. Participating innovators can receive up to $33,000 in funding, based on their work’s milestone achievements, in an effort to bring innovations to life and improve health and well-being for all people.

MSIP and its collaborators aspire to increase access to funding for Mount Sinai inventors, regardless of field, and the fund is available to all teams across the entire Health System. i3 Prism is the newest addition to Mount Sinai’s i3 (innovation, inflection and impact) family of funds, supporting innovation and advancing Mount Sinai technologies.

“i3 Prism will enable women and BIPOC innovators to take the next step in advancing breakthrough health care technologies to benefit patients,” said Erik Lium, PhD, President of MSIP and Chief Commercial Innovation Officer of Mount Sinai. “This fund will directly support i3 Prism awardees in bringing their solutions to the next level.”

The fund was launched by MSIP, in collaboration with the Diversity and Innovation Hub, led by Gary C. Butts, MD, Executive Vice President and Chief Diversity and Inclusion Officer for the Mount Sinai Health System and Dean for Diversity Programs, Policy, and Community Affairs, Icahn School of Medicine at Mount Sinai; Mount Sinai BioDesign, directed by Joshua Bederson, MD, Leonard I. Malis, MD/Corinne and Joseph Graber Professor and System Chair of Neurosurgery, and Benjamin Rapoport, MD, PhD, Assistant Professor of Neurosurgery; the Graduate School of Biomedical Sciences, led by its Dean, Marta Filizola, PhD, Sharon and Frederick Klingenstein/Nathan Kase, MD Professor; the Windreich Department of Artificial Intelligence and Human Health, chaired by Thomas J. Fuchs, DrSc, Barbara T. Murphy, MD Professor of Artificial Intelligence and Human Health; the BioMedical Engineering and Imaging Institute at Icahn Mount Sinai, directed by Zahi Fayad, PhD, Lucy G. Moses Professor in Medical Imaging and Bioengineering; and the Mount Sinai ConduITS – Institutes for Translational Sciences, directed by Rosalind Wright, MD, MPH, Principal Investigator and Dean for Translational Biomedical Sciences.

About Mount Sinai Innovation Partners (MSIP)

Mount Sinai Innovation Partners (MSIP) is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into healthcare products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit ip.mountsinai.org/ or find MSIP on LinkedIn, Twitter, Facebook, Medium, and YouTube.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

SOMERSET, N.J. (PRWEB)
April 19, 2022

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that Patrick Murphy, Director of Continuous Improvement, Technology and Engineering at Catalent’s Philadelphia facility, will be co-hosting a workshop at the upcoming Global Clinical Supplies Group (GCSG) 2022 Annual U.S. Conference, which is to be held at the Hyatt Hill Country Resort & Spa, San Antonio, Texas, from May 1-4, 2022.

The workshop, entitled “Using Value Stream Mapping to Improve Clinical Supply Chain Efficiency”, will take place on May 3 at 1:45 p.m. CDT, and again on the following day at 1 p.m. The session will focus on how clinical supply chains can utilize value stream mapping, which is a lean management method that allows a product delivery process to be visualized, analyzed and improved.

Also at the event, Michael McNear, Catalent’s Director of Operations at its San Diego clinical supply facility, will participate in a panel session entitled, “Clinical Trial Supplies: Creating (& Keeping) the Workforce of the Future”. The session, at 3 p.m. CDT on May 3, will see industry experts discuss current recruitment methods, and how the practice needs to adapt to hire and keep talent in order to maintain organizations’ needs to accomplish current and future goals.

With a network spanning the U.S., U.K., Germany, Singapore, Japan, and China, plus more than 50 additional global depots, Catalent’s clinical supply services can handle a broad range of international compliance and distribution requirements to support global clinical trials.

To find out more information about the event, visit https://www.clinical.catalent.com/events/gcsg-2022-us-annual-conference/.

About Catalent Clinical Supply Services

Catalent solves today’s clinical trial challenges and develops innovative solutions for the future. The company’s commitment to quality and service excellence is evident in its flexible solutions, modern global facilities, and over 25 years’ experience of reliably supplying thousands of studies of all sizes and complexities, all around the world.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually.

Catalent’s expert workforce exceeds 18,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

CARY, N.C. (PRWEB)
April 19, 2022

Flip the Pharmacy, a 5-year transformation program impacting thousands of community-based pharmacies, announced today that Good Neighbor Pharmacy, a franchise business program a part of AmerisourceBergen supporting thousands of community pharmacies across the U.S., has become a national program sponsor. The sponsorship will support the program’s mission of working with pharmacy practice sites to shift the focus from counting and filling prescriptions toward improving a patient’s health.

“I am excited to hear of Good Neighbor Pharmacy’s national sponsorship of Flip the Pharmacy. Good Neighbor Pharmacy is a great partner with community pharmacy. They have been a supporter of community pharmacy transformation from the very beginning. AmerisourceBergen is a wonderful example of a large company who is ‘walking the talk’ in their belief, value, and support of community pharmacy practice. Thank you, Good Neighbor Pharmacy!” said Randy McDonough, Pharm.D., M.S., BCGP, BCPS, FAPhA, director of practice transformation for the Flip the Pharmacy Coordinating Center.

As part of Flip the Pharmacy, pharmacy teams work to transform their community-based pharmacy practice beyond point-in-time, prescription-level transactional models toward longitudinal, patient-level care processes and value-based models. Practice transformation coaches use monthly Flip the Pharmacy Change Packages to work with the pharmacy teams to implement workflow innovations within key practice transformation domains that emphasize delivery of quality patient care and documentation in an eCare Plan platform.

“It’s an absolute pleasure to be a part of the Flip the Pharmacy Program,” said Jenni Zilka, president of Good Neighbor Pharmacy. “At Good Neighbor Pharmacy, we believe wholeheartedly in pharmacy as a site of care and evolving the pharmacy business model beyond prescriptions, and this program is very much aligned to all of this. Flip the Pharmacy will continue to assist thousands of pharmacies nationwide and position them for sustainable success as the practice of pharmacy continues to expand. It’s exciting to see Flip the Pharmacy leverage pharmacy experts as in-person coaches, a model that we have deployed at Good Neighbor Pharmacy with much success. We cannot wait to see the transformation stories that come out of this program.”

Over 1,100 community-based pharmacies are actively involved in the Flip the Pharmacy program (receiving in-person support from a practice transformation coach) and are on track to complete the 24-month program. The Change Packages and other educational resources are free and publicly available to all pharmacies.

“Thanks to Good Neighbor Pharmacy for joining Compliant Pharmacy Alliance and Parata as national sponsors of Flip the Pharmacy. Good Neighbor Pharmacy has long demonstrated a commitment to community-based pharmacy evolution. While other industry actors have developed centralized solutions that offload opportunity away from the local pharmacy, these Flip the Pharmacy sponsors continue to invest in community-based pharmacies, supporting the deployment of tools and resources that bring new opportunities and sustainability towards America’s main street pharmacies,” said Troy Trygstad, Pharm.D., MBA, Ph.D., executive director of CPESN® USA.

“The Community Pharmacy Foundation is proud to be the founding sponsor of Flip the Pharmacy,” added Kelly A. Brock, Pharm.D., executive director of the Community Pharmacy Foundation. “We see the incredible impact Flip the Pharmacy is having in community pharmacies across the country. The Community Pharmacy Foundation greatly appreciates Good Neighbor Pharmacy joining as a national sponsor and recognizes the value of this important investment in community pharmacy practice. With support from all the national sponsors, we will be able to scale Flip the Pharmacy to more community pharmacies which will help us achieve our mission to advance community pharmacy practice.”

About Flip the Pharmacy

Flip the Pharmacy is a five-year pharmacy transformation program aiming to re-work community-based pharmacy practice beyond filling prescriptions and toward an ongoing focus on a patient’s health (or more officially, beyond point-in-time, prescription-level transactional models toward longitudinal and patient-level care processes and value-based models). Using monthly change packages, Flip the Pharmacy coaches work with local pharmacy teams to implement the six key transformation domains with an emphasis on continuing patient care planning with documentation in various eCare plan platforms. Launched in October 2019, the program directly supports over 1,000 pharmacies and impact thousands more. To date, over 1,100 community-based pharmacies are receiving direct coaching and implementation support. Flip the Pharmacy has been made possible through the generous support of Founding Sponsor: Community Pharmacy Foundation and Program Sponsors: Compliant Pharmacy Alliance, Good Neighbor Pharmacy, and Parata Systems. Learn more at flipthepharmacy.com.

About Good Neighbor Pharmacy

Good Neighbor Pharmacy, a part of AmerisourceBergen, is a franchise business program that simplifies the business operations, amplifies the identity, and protects the independence of community pharmacies in the U.S. We partner with these independent businesses to bring out the best in their pharmacy so they can continue delivering the kind of personalized patient care that sets them apart and makes them pillars in their community. Offered through AmerisourceBergen, Good Neighbor Pharmacy is the backbone of community-based pharmacy, uniting thousands of independent businesses by embracing what makes them unique, strengthening the core of their distinctive practices, and giving them the scale they need to thrive in the communities that depend on them.

Share article on social media or email:

GLENDALE, Calif. (PRWEB)
April 19, 2022

Renal Support Network (RSN) shines a light on kidney health and organ donation with a clever animated video series featuring Neff and Nuff, the two animated stars who educate the public about kidney care.

The latest video in the animated series, “Take Your Meds,” stars the Neff and Nuff pals as they explain, in easy-to-understand language, kidney-transplant care and why it’s important to consistently take prescribed medications after surgery. RSN’s founder and president, Lori Hartwell, says, “I often hear that people don’t understand the importance of taking their kidney transplant medications. This prompted us to find a creative way to help them take notice and always remember that it’s vital to take their immunosuppressant medication to honor and protect their gift of life.”

The first animated video in the series is “Kidney Stuff with Neff & Nuff.” In it, the characters bring awareness to what kidneys do and what causes them to fail. It brings attention to the kidneys as the body’s master chemists. According to statistics, 15% of U.S. adults or 37 million people, are estimated to have chronic kidney disease (CKD). As many as 9 in 10 adults with CKD do not know they have CKD. CKD is a silent illness. Neff and Nuff inspire everyone to get their kidneys tested.

“Share Your Spare,” another video in RSN’s animated series, follows Neff and Nuff as the persnickety pals talk about how to keep the body’s kidneys healthy, the great need for kidney donors, and the steps people need to take to share their spares. The inspiration for the two captivating kidney characters was the popularity of RSN’s “Share Your Spare” conversation tool kit, which amplified the need for organ donors. Its success has generated an increase in awareness of deceased kidney donation and living kidney donation.

All of the videos are available at RSNhope.org, and on the Renal Support Network YouTube and Vimeo channels.

We ask that you share this message and videos with your friends and family. Together, we can help make the importance of kidney health and organ donation a household conversation.

Neff and Nuff are brought to life by award-winning producer and animator Steve Moore and film composer Ian Rees who provided the music. Four talented actors/comedians crafted the voices: Jill-Michele Meleán (Neff, English), Joseph D. Reitman (Nuff, English), Sandra Valls (Neff, Spanish), and Andres Mejia (Nuff, Spanish).

RSN is a nonprofit patient-run organization that provides educational and peer support services to those affected by chronic kidney disease (CKD). RSN strives to help those who are newly diagnosed with CKD or on dialysis, as well as kidney transplant recipients, develop their personal coping skills, special talents, and employability by educating and empowering them to take control of the course and management of their disease. RSN empowers people living with kidney disease to become knowledgeable about their illness, proactive in their care, hopeful about their future and make friendships that last a lifetime. To learn more about organ donation, causes of kidney disease, dialysis and transplant treatment options, visit RSNhope.org. Find us on social media @RSNhope.

Share article on social media or email: